- Home
- KG vs SLS Comparison
KG vs SLS Comparison
Compare KG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | SLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.0M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KG | SLS |
|---|---|---|
| Price | $10.38 | $4.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 22.8K | ★ 14.5M |
| Earning Date | 02-15-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 8.50 | N/A |
| Revenue | ★ $26,676,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.08 | ★ N/A |
| Revenue Growth | ★ 1610.20 | N/A |
| 52 Week Low | $8.07 | $0.85 |
| 52 Week High | $36.80 | $5.18 |
Technical Indicators
Market Signals| Indicator | KG | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 65.21 |
| Support Level | $8.77 | $3.69 |
| Resistance Level | $10.74 | $4.42 |
| Average True Range (ATR) | 0.86 | 0.60 |
| MACD | 0.34 | -0.00 |
| Stochastic Oscillator | 79.96 | 64.99 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.